Shear-dependent platelet aggregation by ChAdOx1 nCoV-19 vaccine: a novel biophysical mechanism for arterial thrombosis

Y Yiyao Catherine Chen (1School of Biomedical Engineering, The University of Sydney, Darlington, NSW, Australia) N Naveen Eugene Louis Richard Louis (1School of Biomedical Engineering, The University of Sydney, Darlington, NSW, Australia) A Angela Huang (2Atherothrombosis and Vascular Biology, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia) A Allan Sun (1School of Biomedical Engineering, The University of Sydney, Darlington, NSW, Australia) A Alexander Dupuy (1School of Biomedical Engineering, The University of Sydney, Darlington, NSW, Australia) L Laura Moldovan (1School of Biomedical Engineering, The University of Sydney, Darlington, NSW, Australia) T Tiana Pelaia (1School of Biomedical Engineering, The University of Sydney, Darlington, NSW, Australia) J Jianfang Ren (1School of Biomedical Engineering, The University of Sydney, Darlington, NSW, Australia) T Taylor S. Cohen S Sarah C. Gilbert (7Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom) H Huyen Tran (8Department of Clinical Haematology, Alfred Hospital, Melbourne, VIC, Australia) K Karlheinz Peter (2Atherothrombosis and Vascular Biology, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia) J James D. McFadyen L Lining Arnold Ju

Abstract

Abstract Rare thrombotic events associated with ChAdOx1 nCoV-19 (ChAdOx1) vaccination have raised concerns; however, the underlying mechanisms remain elusive. Here, we report a novel biophysical mechanism by which ChAdOx1 directly interacts with platelets under arterial shear conditions, potentially contributing to postvaccination arterial thrombosis. Using microfluidic post assays, we demonstrate that ChAdOx1 induces shear-dependent platelet aggregation, distinct from conventional von Willebrand factor–mediated adhesion. This interaction is mediated by platelet integrin αIIbβ3 and requires biomechanical activation, explaining the absence of significant binding under static conditions. Molecular dynamics simulations and docking studies reveal preferential binding of ChAdOx1's penton arginine-glycine-aspartic acid (RGD) motif to the activated conformation of αIIbβ3. Inhibiting integrin αIIbβ3 completely abolishes ChAdOx1-induced platelet aggregation, whereas blocking glycoprotein (GP) Ib has minimal effect, confirming a mechanism that bypasses the conventional GPIb-dependent platelet adhesion pathway. Mutagenesis of the RGD motif to AAA eliminates platelet binding, verifying the specificity of this interaction. These findings provide a potential explanation for the association between ChAdOx1 vaccination and arterial thrombotic events, distinct from vaccine-induced immune thrombotic thrombocytopenia. Our results highlight the importance of considering biomechanical factors in vaccine-related thrombotic complications and suggest that shear-dependent integrin activation may be another determinant in the pathogenesis of these rare adverse events.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue 4
Published July 24, 2025
Pages 496-503
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (14)

Y

Yiyao Catherine Chen

1School of Biomedical Engineering, The University of Sydney, Darlington, NSW, Australia

N

Naveen Eugene Louis Richard Louis

1School of Biomedical Engineering, The University of Sydney, Darlington, NSW, Australia

A

Angela Huang

2Atherothrombosis and Vascular Biology, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia

A

Allan Sun

1School of Biomedical Engineering, The University of Sydney, Darlington, NSW, Australia

A

Alexander Dupuy

1School of Biomedical Engineering, The University of Sydney, Darlington, NSW, Australia

L

Laura Moldovan

1School of Biomedical Engineering, The University of Sydney, Darlington, NSW, Australia

T

Tiana Pelaia

1School of Biomedical Engineering, The University of Sydney, Darlington, NSW, Australia

J

Jianfang Ren

1School of Biomedical Engineering, The University of Sydney, Darlington, NSW, Australia

T

Taylor S. Cohen

S

Sarah C. Gilbert

7Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

H

Huyen Tran

8Department of Clinical Haematology, Alfred Hospital, Melbourne, VIC, Australia

K

Karlheinz Peter

2Atherothrombosis and Vascular Biology, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia

J

James D. McFadyen

L

Lining Arnold Ju